Altasciences: Altreos alliance to support 'rapidly evolving area of abuse potential assessments'

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/Oleksandr Boliukh)
(Image: Getty/Oleksandr Boliukh)
Altasciences has entered into a strategic alliance with Altreos Research Partners to help clients navigate the “complexities of human abuse potential studies,” says CEO.

Altasciences Clinical Research is a mid-sized contract research organization (CRO) that encompasses Algorithme Pharma and Vince & Associates Clinical Research. Altreos provides scientific, regulatory, and operational input on human abuse potential (HAP) assessments.

Under the new strategic alliance, Altreos will support Altasciences’ clients from initial planning to regulatory submission.

In addition to HAP assessments, the alliance also expands Altasciences’ ability to provide human abuse liability trials (HAL) for new chemical entities (NCEs) and abuse-deterrent formulations (ADFs).

The alliance was established to formalize the existing relationship between Altasciences/Vince & Associates and Altreos Research Partners “as well as extend a wider range of complimentary services to our biopharmaceutical clients,”​ said Dr. Brad Vince, CEO and medical director at Altasciences’ Kansas facility.

The alliance is set to last a minimum of three years, he told us.

Vince said: “Given the rapidly evolving area of abuse potential assessments of new molecular entities and abuse-deterrent formulations, the collaboration between Altasciences/Vince & Associates and Altreos provides our clients with up to date scientific and regulatory expertise coupled with an operational unit that is equipped to manage the complexities of human abuse potential studies.”

 

Related topics: Clinical Development

Related news

Show more

Follow us

Products

View more

Webinars